Comparison of Improvement in 2-Year Survival Rate of Patients with Stage II-III Non-Small Cell Lung Cancer Treated with Different Durations of Chinese Patent Medicine: A Retrospective Cohort Study.
Front Pharmacol
; 12: 719802, 2021.
Article
en En
| MEDLINE
| ID: mdl-34539404
Texto completo:
1
Bases de datos:
MEDLINE
Tipo de estudio:
Etiology_studies
/
Guideline
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Front Pharmacol
Año:
2021
Tipo del documento:
Article
País de afiliación:
China